Compile Data Set for Download or QSAR
Report error Found 187 Enz. Inhib. hit(s) with all data for entry = 8662
TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298445(US10125100, Example 42 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 3nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM337707(US9751837, Example 17(am) | US10392346, Example 17...)
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298449(US10125100, Example 47 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 4nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM255476(US9499486, 1 | US10125100, Example 1 | US9751837, ...)
Affinity DataIC50: 5nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298426(US10125100, Example 17(af) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 5nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298439(US10125100, Example 22 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298442(US10125100, Example 39 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 6nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298436(US10125100, Example 19 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 8nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298436(US10125100, Example 19 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298449(US10125100, Example 47 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 8nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298392(US10125100, Example 14 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298425(US10125100, Example 17(ae) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 10nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298441(US10125100, Example 36 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 10nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM255476(US9499486, 1 | US10125100, Example 1 | US9751837, ...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 11nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298430(US10125100, Example 17(aj) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 12nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298431(US10125100, Example 17(ak) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 12nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298444(US10125100, Example 41 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 13nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM255476(US9499486, 1 | US10125100, Example 1 | US9751837, ...)
Affinity DataIC50: 14nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298429(US10125100, Example 17(ai) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 14nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298438(US10125100, Example 21 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 15nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298449(US10125100, Example 47 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 15nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM411450(US10392346, Example 17(a) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298404(US10125100, Example 17(j) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298438(US10125100, Example 21 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 16nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM411487(US10392346, Example 17(ag) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298439(US10125100, Example 22 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298442(US10125100, Example 39 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetTyrosine-protein kinase SYK(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 17nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298392(US10125100, Example 14 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 19nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298407(US10125100, Example 17(m) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 19nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298441(US10125100, Example 36 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 19nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298375(US10125100, Example 2 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298375(US10125100, Example 2 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298396(US10125100, Example 17(b) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298410(US10125100, Example 17(p) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298421(US10125100, Example 17(aa) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 20nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM411488(US10392346, Example 17(ah) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
Ligand InfoSimilars
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298435(US10125100, Example 17(cp) | US9751837, Example 17...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298446(US10125100, Example 44 | (4-((4-((4-(3-(5-(tert-Bu...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298450(US10125100, Example 48 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 20nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298382(US10125100, Example 7 | 4-((4-((4-(3-(5-(tert-Buty...)
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298404(US10125100, Example 17(j) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 21nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298410(US10125100, Example 17(p) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298445(US10125100, Example 42 | 4-((4-((4-(3-(5-(tert-But...)
Affinity DataIC50: 21nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298394(US10125100, Example 16 | 4-[[4-[[4-[[5-tert-Butyl-...)
Affinity DataIC50: 22nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298436(US10125100, Example 19 | 2-(2-(2-(4-((4-((4-(3-(5-...)
Affinity DataIC50: 22nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298390(US10125100, Example 12 | 1-[5-tert-Butyl-3-(methan...)
Affinity DataIC50: 23nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Topivert Pharma

US Patent
LigandPNGBDBM298421(US10125100, Example 17(aa) | 4-[[4-[[4-[[5-tert-bu...)
Affinity DataIC50: 24nMAssay Description:c-Src and Syk: The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

TargetBaculoviral IAP repeat-containing protein 2 [174-256](Human)
Topivert Pharma

US Patent
LigandPNGBDBM298407(US10125100, Example 17(m) | 4-[[4-[[4-[[5-tert-but...)
Affinity DataIC50: 25nMAssay Description:p38 MAPKγ: The inhibitory activities of compounds of the invention against p38MAPKγ (MAPK12: Invitrogen), are evaluated in a similar fashio...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/20/2020
Entry Details
Go to US Patent

Displayed 1 to 50 (of 187 total ) | Next | Last >>
Jump to: